COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
A comparison between five-days per week versus daily dialysis in patients starting peritoneal dialysis on clinical outcomes and quality of life
Scientific title
The effect of incremental peritoneal dialysis on clinical outcomes and quality of life in incident dialysis patients.
Secondary ID [1] 299641 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney failure 314960 0
Condition category
Condition code
Renal and Urogenital 313306 313306 0 0
Kidney disease

Study type
Description of intervention(s) / exposure
Incremental peritoneal dialysis, by performing five days a week of dialysis instead of daily, will be compared to daily peritoneal dialysis, in incident peritoneal dialysis patients. This type of dialysis is usually performed on a daily basis, by the patients in their own homes. There is a wide range of treatment duration (from 8 to 24 hours, depending on patient preference and their dialysis requirement, and usually lasts 3-5 years). Peritoneal dialysis can either be done manually (aided by gravity), or using an automated machine pump - both are the standard of care and are chosen by patients depending on their lifestyle. This study is not a comparison between manual vs automated techniques; rather, it aims to compare 5 days versus daily dialysis.

Adherence of incremental or daily peritoneal dialysis will be reviewed during three monthly clinic visits, telephone reviews, as well as assessing remote monitoring data built in to dialysis machines (in participating units).
Intervention code [1] 315901 0
Treatment: Other
Comparator / control treatment
The control group is formed by patients on daily peritoneal dialysis - the current standard of care. Specifically, peritoneal dialysis will be done 7 days a week, by the patients, in their own homes. The treatment duration is again variable, ranging from 8-24 hours, depending on patient preference and their dialysis requirement, for up to 3-5 years. Either manual or automated peritoneal dialysis will be performed by this group, as determined by patient preference.
Control group

Primary outcome [1] 321785 0
Duration of incremental peritoneal dialysis until requiring daily dialysis (when kidney creatinine clearance < 50 L/week/1.73m^2) as determined by 24 hour urine collection, or if participants display evidence of inadequate dialysis clinically, or on blood tests for urea and creatinine)
Timepoint [1] 321785 0
Every 3 months from study entry for 12 months for the 24 hour urine collections.
Clinical review by a doctor every 3 months.
Blood tests every month.
Secondary outcome [1] 376195 0
Quality of life score (KDQOL SF 1.3)
Timepoint [1] 376195 0
At baseline, 6 and 12 months post randomisation
Secondary outcome [2] 376196 0
Residual kidney creatinine clearance (L/week/1.73m^2) on 24 hour urine collection.
Timepoint [2] 376196 0
Every 3 months from study entry for 12 months for the 24 hour urine collections.
Secondary outcome [3] 376197 0
Peritoneal membrane D/P creatinine on PET/Adequest test (a test that compares the change of creatinine concentration in the spent dialysate at time 0, 1 and 4 hours after infusion into the abdomen).
Timepoint [3] 376197 0
At 6 weeks after starting study and at 1 year
Secondary outcome [4] 376198 0
Safety (composite outcome of hospital admissions for fluid overload (determined clinically by physical examination) and hyperkalaemia (measuring potassium on a blood test).
Hospital admissions will be determined by a number of ways, including patient reporting, automated alert from electronic medical record programme to the trial doctor and trial coordinator, or retrospective review of electronic medical records.
Timepoint [4] 376198 0
Assessed every 3 months for 12 months.
Secondary outcome [5] 376199 0
Peritonitis episodes, reported as episodes per year. Peritonitis is defined as a peritoneal dialysate polymorphonuclear cell count >100 million/L (dialysate microscopy), with evidence of cloudy fluid or abdominal pain (patient medical records).
Peritonitis episodes will be tracked by the home dialysis unit of the hospital and reported to the study doctor and study coordinator, or be retrospectively reviewed on eletronic medical records.
Timepoint [5] 376199 0
At 1 year post randomisation

Key inclusion criteria
Able to provide informed consent.
Residual kidney creatinine clearance >50 L/week/1.73m^2 on 24 hour urine collection.
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Been on haemodialysis or peritoneal dialysis for >3 months.
Life expectancy <1 year.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelope
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using randomisation table created by a computer software
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Randomised 1:1 (incremental : control)
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
As this study is a pilot, the primary outcome of "duration of incremental peritoneal dialysis" until needing daily dialysis does not allow power calculation. This result will be reported using descriptive statistics.

The secondary end points will allow comparison between the incremental vs. control groups, using mixed linear models to compare rate of decline of residual kidney function, Kaplan Meier statistics to compare time to first peritonitis, and ANOVA with repeat measures for mean quality of life scores.

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 15041 0
Box Hill Hospital - Box Hill
Recruitment hospital [2] 16753 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [3] 16754 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment postcode(s) [1] 28328 0
3128 - Box Hill
Recruitment postcode(s) [2] 28329 0
3128 - Box Hill Central
Recruitment postcode(s) [3] 30374 0
3084 - Heidelberg
Recruitment postcode(s) [4] 30375 0
3168 - Clayton

Funding & Sponsors
Funding source category [1] 304115 0
Name [1] 304115 0
Eastern Health Integrated Renal Service
Address [1] 304115 0
5 Arnold Street
Box Hill VIC 3128
Country [1] 304115 0
Primary sponsor type
Eastern Health
5 Arnold Street
Box Hill VIC 3128
Secondary sponsor category [1] 304330 0
Name [1] 304330 0
Address [1] 304330 0
Country [1] 304330 0

Ethics approval
Ethics application status
Ethics committee name [1] 304602 0
Monash Health HREC
Ethics committee address [1] 304602 0
Research Support Services
Level 2, i Block
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168
Ethics committee country [1] 304602 0
Date submitted for ethics approval [1] 304602 0
Approval date [1] 304602 0
Ethics approval number [1] 304602 0
Reference number RES-19-0000-101A

Brief summary
In order to prolong peritoneal dialysis [PD] technique survival, clinicians not only need to focus on protecting patient’s residual kidney function and peritoneal membrane integrity, they also need to address the impact of PD on patient’s daily living. One potential solution is the use of incremental PD (5 days a week dialysis). We have designed an investigator-initiated study to answer the following questions:
Is incremental PD a feasible dialysis prescription?
• Can PD patients be safely maintained on incremental PD
• How long does incremental PD last, until needing daily PD

By having regular peritoneal membrane resting, does incremental PD
• Maintain residual renal function and urine output?
• Improve patient’s life participation?
• Better preserve peritoneal membrane function?

The study will recruit adult patients who have commenced peritoneal dialysis in the previous 3 months and has been designed to fit in with PD patients' standard of care so minimal additional pathology testing will be required.

We expect the incremental dialysis group to report better quality of life and demonstrate non-inferiority in terms of safety data and peritonitis rates.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 97542 0
Dr Louis Huang
Address 97542 0
Eastern Health
Department of Renal Medicine
Level 2, 5 Arnold Street
Box Hill VIC 3128
Country 97542 0
Phone 97542 0
+61 3 98953333
Fax 97542 0
Email 97542 0
Contact person for public queries
Name 97543 0
Dr Louis Huang
Address 97543 0
Eastern Health
Department of Renal Medicine
Level 2, 5 Arnold Street
Box Hill VIC 3128
Country 97543 0
Phone 97543 0
+61 3 98953333
Fax 97543 0
Email 97543 0
Contact person for scientific queries
Name 97544 0
Dr Louis Huang
Address 97544 0
Eastern Health
Department of Renal Medicine
Level 2, 5 Arnold Street
Box Hill VIC 3128
Country 97544 0
Phone 97544 0
+61 3 98953333
Fax 97544 0
Email 97544 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
What supporting documents are/will be available?
No other documents available
Summary results
No Results